ACRV Relative Valuation
ACRV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACRV is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.25
P/B
Median3y
1.21
Median5y
1.21
-151.59
FCF Yield
Median3y
-28.29
Median5y
-28.29
Competitors Valuation Multiple
The average P/S ratio for ACRV's competitors is 62.72, providing a benchmark for relative valuation. Acrivon Therapeutics Inc Corp (ACRV) exhibits a P/S ratio of 310.28, which is 394.70% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
BH
Biglari Holdings Inc
226.560
USD
-2.73%
HPP
Hudson Pacific Properties Inc
2.180
USD
+6.34%
YORW
York Water Co
34.950
USD
-0.71%
TCBX
Third Coast Bancshares Inc
30.310
USD
+1.71%
SVC
Service Properties Trust
1.900
USD
+5.56%
ALNT
Allient Inc
21.630
USD
+1.31%
MTLS
Materialise NV
5.190
USD
+0.97%
CVRX
CVRx Inc
7.290
USD
-0.41%
API
Agora Inc
3.400
USD
+3.66%
FC
Franklin Covey Co
20.590
USD
+1.38%
FAQ
Is Acrivon Therapeutics Inc (ACRV) currently overvalued or undervalued?
Acrivon Therapeutics Inc (ACRV) is now in the Fair zone, suggesting that its current forward PS ratio of 310.28 is considered Fairly compared with the five-year average of 22.67. The fair price of Acrivon Therapeutics Inc (ACRV) is between to according to relative valuation methord.
What is Acrivon Therapeutics Inc (ACRV) fair value?
How does ACRV's valuation metrics compare to the industry average?
What is the current P/B ratio for Acrivon Therapeutics Inc (ACRV) as of May 02 2025?
What is the current FCF Yield for Acrivon Therapeutics Inc (ACRV) as of May 02 2025?
What is the current Forward P/E ratio for Acrivon Therapeutics Inc (ACRV) as of May 02 2025?